ADM (NYSE: ADM), a global leader in innovative solutions from nature, today announced that spore-forming probiotic DE111™* (Bacillus subtilis) has received official approval from the Therapeutic Goods Administration (TGA), a part of the Australian Department of Health. This extends DE111™’s availability into new regions**, following the recent approval from the National Health Commission (NHC) in China.  “This is an important milestone for ADM, as it marks the first Bacillus subtilis … [Read more...] about ADM’s spore-forming probiotic DE111 receives approval from the Therapeutic Goods Administration (TGA) in Australia